3. Hashem O A., et al. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Frontiers in Pharmacology. 2017, 8: 1-15.
因此，通过打断PD-1/PD-L1信号通路，可以恢复T细胞抗肿瘤活性，进一步杀伤肿瘤细胞。O药和K药的研发历程 自1992年本庶佑教授发现PD-1蛋白，到2014年K药和O药相继上市，中间经历了22年，可见药物研发长路漫漫。2000年，本庶佑教授与日本的一家制药企业小野制药（ONO PHARMACEUTICAL CO., LTD）合作，共同开发PD-1抑制...
[2].杨宝峰. 药理学. 北京: 人民卫生出版社, 2013; 第8版: 7-17. [3].Yu Z, Lennon V A. Mechanism of Intravenous Immune Globulin Therapy in Antibody-Mediated Autoimmune Diseases[J]. The New England Journal of Medicine, 1999, 340(3): 227-228. [4].Brahmer JR, et al. Phase I study...
Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB et al (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793–800 https://en.wikipedia.org/wiki/Immune_checkpoint https://go.drugbank.com/...
Molecular mechanism of PD-1/PD-L1 blockadevia anti-PD-L1 antibodies atezolizumab and durvalumab Safety profiles of anti-CTLA‑4 and anti‑PD‑1 antibodies alone and in combination Tcell co-stimulatory receptor CD28 is a primary target for PD-1–mediatedinhibition Rescueof exhausted CD8 T ce...
科学家们认为,NK细胞上PD-L1表达可识别出易被NK细胞破坏的肿瘤,从而为探索新的免疫治疗途径提供可能。该研究发表在《癌症发现》(《Cancer Discovery》)上,题为“The mechanism of anti-PD-L1 antibody efficacy against PD-L1 negative tumors identifies...
3. Hashem O A., et al. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Frontiers in Pharmacology. 2017, 8: 1-15.
1.Borst J, Busselaar J, Bosma DMT, Ossendorp F. Mechanism of action of PD-1 receptor/ligand targeted cancer immunotherapy. Eur J Immunol. 2021 Aug;51(8):1911-1920.2.Zhiyong Li, Zhuowei Liu, et al.Preliminary results from a phase II study of tislelizumab combined with radiotherapy as...
17.Topalian, S.L., et al., Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.Nat Rev Cancer,2016. 16(5): p. 275-87. 18.Ward, J.P., M.M. Gubin, and R.D. Schreiber, The R...
Here, we provide an update of current progress of PD-L1 and PD-1 post-translational regulations and highlight the mechanism-based combination therapy strategies for a better treatment of human cancer.doi:10.1016/j.semcancer.2021.04.002Xiaoming Dai...